The X-linked Hypophosphatemia Market is comprised of drugs used for the treatment of x-linked hypophosphatemia, which is a rare, inherited disorder caused by defects in the PHEX gene that cause low levels of phosphorus in the blood and bones. Some key advantages of drugs in this market include their ability to increase phosphate levels in patients and strengthen bones. Treatment is needed as x-linked hypophosphatemia can lead to weakened bones and poor growth in children.
The X-linked Hypophosphatemia Market is estimated to be valued at US$ 1.5 Bn in 2024 and is expected to exhibit a CAGR of 9.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the x-linked hypophosphatemia are Ultragenyx Pharmaceutical,Kyowa Kirin,Ascendis Pharma,Pfizer,Chiesi Farmaceutici. Ultragenyx Pharmaceutical currently dominates the market with its drugs DKPG and Burosumab, while Kyowa Kirin's recombinant PHEX therapy is in late stage clinical trials.
The global x-linked hypophosphatemia presents lucrative growth opportunities for players as the disorder remains underdiagnosed. Increasing awareness campaigns by patient advocacy groups and newborn screening programs could significantly boost case identification.
Major companies are expanding their geographical presence through regulatory approvals and geographical expansions. For instance, in 2023, Burosumab received approval in China, expanding international availability of the drug. Further approval in other Asian and Latin American countries are expected in the coming years.
Market Drivers
- Rising prevalence of x-linked hypophosphatemia worldwide due to better screening programs. The global prevalence is estimated to be around 1 in 20,000 newborns.
- Growing clinical evidence on the Bone mineralization effects of drugs driving their long-term adoption.
Market Restraints
- High cost of drugs limiting accessibility in low income countries. For example, the average annual cost of Burosumab is over $200,000 in the United States.
- Delay in diagnosis and referral to specialists due to lack of disease awareness among primary physicians.
Segment Analysis
The X-linked Hypophosphatemia Market is dominated by the drug treatment segment. This is because X-linked hypophosphatemia is a genetic disorder requiring lifelong treatment. Drugs like Fosrenol, Phoslyra, and Besphera are the core treatment options prescribed by physicians to control serum phosphorus levels in patients. These drugs work by reducing the absorption of phosphorus from food in the gut and promoting excretion of excess phosphorus through urine. Though supplements are also given to fulfill the phosphate requirement, drug therapy forms the mainstreamstay of x-linked hypophosphatemia management.
Global Analysis
North America holds the largest share in the X-linked Hypophosphatemia Market and the trend is expected to continue during the forecast period. This is owing to the growing diagnosis rates in the US and Canada along with high adoption of drugs owing to good reimbursement policies and healthcare infrastructure. Europe is also a major revenue generator attributed to increasing awareness about rare diseases in countries like Germany, UK, and France. However, Asia Pacific is anticipated to witness the highest growth during the forecast period. This can be credited to the rising income levels, improving healthcare access and expanding patient pool in developing nations like China and India.
Get more insights on this topic: https://www.dailyprbulletin.com/x-linked-hypophosphatemia-market-in-trends-by-increasing-prevalence-of-bone-deformities/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
What Are The Key Data Covered In This X-linked Hypophosphatemia Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the X-linked Hypophosphatemia Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the X-linked Hypophosphatemia Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- X-linked Hypophosphatemia Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of X-linked Hypophosphatemia Market vendors
FAQ’s
Q.1 What are the main factors influencing the X-linked Hypophosphatemia Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top X-linked Hypophosphatemia Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the X-linked Hypophosphatemia Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it